Amvuttra™ (vutrisiran)

Amvuttra (vutrisiran) is covered only for adult (≥18) patients for the polyneuropathy of hereditary transthyretin‑mediated amyloidosis and is not covered for other indications or for patients with a history of liver transplantation. Approval (up to 12 months) requires documented TTR gene mutation, clinical evidence of symptomatic polyneuropathy, prescription by or consultation with a neurologist/geneticist/amyloidosis specialist, and follows the recommended dosing of 25 mg subcutaneously every 3 months with supporting documentation.

"Amvuttra is indicated for the treatment of the polyneuropathy of hereditary transthyretinmediated amyloidosis in adults."

Sign up to see full coverage criteria, indications, and limitations.